Nabriva Therapeutics plc is a clinical‐stage biopharmaceutical company focused on the research and development of novel anti‐infective agents to treat serious bacterial infections. The company’s lead product, XENLETA® (lefamulin), is a first‐in‐class pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community‐acquired bacterial pneumonia (CABP) in adults. In addition to its oral and intravenous formulations of lefamulin, Nabriva is advancing CONTEPO™ (finafloxacin) for complicated urinary tract infections, as well as other preclinical programs targeting multidrug‐resistant pathogens.
Founded in 2006, Nabriva is headquartered in Dublin, Ireland, with U.S. operations based in King of Prussia, Pennsylvania. The company has secured regulatory approvals and collaborations to support commercialization efforts in North America, Europe and select global markets. Its strategic partnerships extend to contract manufacturing organizations and regional distributors, enabling a seamless supply chain and market access for its antibacterial therapies. Nabriva’s robust patent portfolio underpins its novel chemistry, with protections in place for multiple formulations and indications.
Under the leadership of President and Chief Executive Officer Paul C. Rubin, MD, Nabriva’s management team comprises seasoned executives in clinical development, regulatory affairs and commercial operations. The company’s board and scientific advisory committees include experts in infectious diseases, antibiotic resistance and translational medicine, reinforcing its commitment to rigorous clinical evaluation and safe patient outcomes. Nabriva maintains active engagement with key opinion leaders, patient advocacy groups and public health agencies to address the global threat of antibiotic resistance.
Looking ahead, Nabriva aims to expand the clinical utility of its existing products through additional indications and formulation enhancements, while advancing its pipeline candidates toward late‐stage trials. With a focus on unmet medical needs in serious bacterial infections, the company pursues regulatory designations and potential partnerships to accelerate market adoption and maximize patient access worldwide. Nabriva’s long‐term strategy emphasizes sustainable growth through innovation in the field of anti‐infectives and strategic collaborations to combat the evolving landscape of antimicrobial resistance.
AI Generated. May Contain Errors.
Free NBRV Stock Alerts